FGFR2 and cholangiocarcinoma: In Phase II trials, infigratinib demonstrated an objective response rate of 23.1% in patients with FGFR2 fusion-positive CCA who had previously received gemcitabine-based therapy, suggesting its potential as an effective treatment [147].